metoclopramide has been researched along with Tardive Dyskinesia in 6 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Tardive Dyskinesia: Drug-related movement disorder characterized by uncontrollable movements in certain muscles. It is associated with a long-term exposure to certain neuroleptic medications (e.g., METOCLOPRAMIDE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A PubMed, Google Scholar, and Cross Reference search was done using the key words and combined searches: drug-drug interaction, gastroparesis, metoclopramide, natural history, pharmacokinetics, pharmacodynamics, drug-drug interaction, outcome, risk factors, tardive dyskinesia." | 9.01 | Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. ( Al-Saffar, A; Hellström, PM; Lennernäs, H, 2019) |
| " Food and Drug Administration (FDA) placed a black box warning on metoclopramide (MCP) due to the increased risks and prevalence of tardive dyskinesia (TD)." | 7.85 | MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia. ( Caylor, ML; Culbertson, VL; Dang, HK; Economen, PJ; Flynn, ST; Ham, AG; Johnson, RW; Tao, A; Tivis, RD; Xu, D, 2017) |
| "A PubMed, Google Scholar, and Cross Reference search was done using the key words and combined searches: drug-drug interaction, gastroparesis, metoclopramide, natural history, pharmacokinetics, pharmacodynamics, drug-drug interaction, outcome, risk factors, tardive dyskinesia." | 5.01 | Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. ( Al-Saffar, A; Hellström, PM; Lennernäs, H, 2019) |
| " Submissions related to metoclopramide by far exceeded reports about other agents and mostly described tardive dyskinesia or other neurological concerns." | 3.85 | From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis. ( Bielefeldt, K, 2017) |
| " Food and Drug Administration (FDA) placed a black box warning on metoclopramide (MCP) due to the increased risks and prevalence of tardive dyskinesia (TD)." | 3.85 | MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia. ( Caylor, ML; Culbertson, VL; Dang, HK; Economen, PJ; Flynn, ST; Ham, AG; Johnson, RW; Tao, A; Tivis, RD; Xu, D, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lacy, BE | 1 |
| Cangemi, DJ | 1 |
| Bielefeldt, K | 1 |
| Xu, D | 1 |
| Ham, AG | 1 |
| Tivis, RD | 1 |
| Caylor, ML | 1 |
| Tao, A | 1 |
| Flynn, ST | 1 |
| Economen, PJ | 1 |
| Dang, HK | 1 |
| Johnson, RW | 1 |
| Culbertson, VL | 1 |
| Al-Saffar, A | 1 |
| Lennernäs, H | 1 |
| Hellström, PM | 1 |
| Thomson, AM | 1 |
| Wallace, J | 1 |
| Kobylecki, C | 1 |
| Kass, JS | 1 |
| Rose, RV | 1 |
2 reviews available for metoclopramide and Tardive Dyskinesia
| Article | Year |
|---|---|
Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited.
Topics: Antiemetics; Dopamine D2 Receptor Antagonists; Gastroparesis; Humans; Metoclopramide; Risk Factors; | 2019 |
Liability and Failure to Warn a Patient.
Topics: Dopamine D2 Receptor Antagonists; Drug-Related Side Effects and Adverse Reactions; Humans; Liability | 2019 |
4 other studies available for metoclopramide and Tardive Dyskinesia
| Article | Year |
|---|---|
Controversies in Gastroparesis: Discussing the Sticky Points.
Topics: Abdominal Pain; Antiemetics; Chronic Disease; Diabetes Complications; Diagnosis, Differential; Diagn | 2021 |
From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antiemetics; Databases, Factual; Deglutition D | 2017 |
MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia.
Topics: Antipsychotic Agents; Databases, Factual; Drug Interactions; Drug-Related Side Effects and Adverse R | 2017 |
Tardive dyskinesia after drug withdrawal in two older adults: Clinical features, complications and management.
Topics: Aged; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2019 |